Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FR?.

Abstract: Methods for detecting one or more target bacteria in a test sample are provided. It is shown herein that photosensitizers combined with intense light exposure reduce fluorescing background due to non-bacterial particles. This permits detection of subsequently labeled target bacterial cells (e.g., using a fluorescently labeled antibody) against a largely black background. In particular examples, the methods include incubating the test sample in a growth medium that permits growth of bacteria present in the sample, contacting the sample with a photo-sensitizer; exposing the sample to light under conditions sufficient for the photo-sensitizer to photobleach contaminating non-bacterial particulates present in the sample. The bacteria can then be substantially separated from the sample, thereby generating an isolated bacterial sample. The method can also include contacting the isolated bacterial sample with a binding agent specific for the one or more target bacteria, and detecting the one or more target bacteria.

Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.

Abstract: Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.

Abstract: This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKNIA) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic (CDDO) to attenuate such replication.

Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.